Methylation of Methyl 4-Hydroxy-2-thioxo-1,2-dihydroquinoline-3-carboxylate: Synthetic, Crystallographic, and Molecular Docking Studies

Sergiy М. Kovalenko, Oleksandr G. Drushlyak, Svitlana V. Shishkina, Irina S. Konovalova, Illia O. Mariutsa, N. D. Bunyatyan, Dmitry V. Kravchenko, Vladimir V. Ivanov, Alexandre V. Ivachtchenko, Thierry LangerMolecules 2020 · DOI

TL;DR

Researchers have synthesized and characterized new quinoline derivatives, exploring their regioselectivity in methylation reactions. These compounds show promise as potent inhibitors of Hepatitis B Virus (HBV) replication, with experimental studies confirming significant inhibition at low concentrations.

What Problem Does This Paper Address?

The development of effective antiviral agents, particularly for Hepatitis B Virus (HBV), remains a critical challenge. While quinoline derivatives are known for their antibacterial properties, their potential as antiviral agents, specifically against HBV, is less explored. This paper addresses the need for new HBV inhibitors by investigating the synthesis and biological activity of novel quinoline-3-carboxylate derivatives. A key aspect is understanding the regioselectivity of methylation reactions on a specific quinoline core, which is crucial for designing and synthesizing libraries of related compounds with predictable properties.

Methods

The study employed a multi-faceted approach:

  • Organic Synthesis: The core quinoline structure, methyl 4-hydroxy-2-thioxo-1,2-dihydroquinoline-3-carboxylate, was synthesized via a one-pot condensation. Subsequent methylation reactions with methyl iodide (CH₃I) were investigated under varying conditions (base, solvent, temperature, time) to understand regioselectivity.
  • Spectroscopic and Analytical Techniques: The synthesized compounds were characterized using elemental analysis, 1H-NMR, 13C-NMR, LC/MS, and single-crystal X-ray diffraction to confirm their structures and purity.
  • Quantum Chemical Calculations: DFT (B3LYP/cc-pVDZ) calculations were performed on the anion of a key intermediate to understand its electronic structure and geometry, aiding in the interpretation of reaction outcomes.
  • Molecular Docking Simulations: These simulations were used to predict the binding affinity of the synthesized compounds to the Hepatitis B Virus (HBV) capsid protein (specifically the 5E0I complex), identifying potential inhibitors.
  • In Vitro Biological Assays: Experimental studies using a human hepatoma cell line (HepG2/NTCP) infected with HBV were conducted to evaluate the actual antiviral activity and cytotoxicity of the most promising compounds.

Datasets

Not discussed in the paper. The study relies on established protein structures (PDB codes like 5E0I) for molecular docking and a specific cell line model for in vitro testing.

Key Insights and Ideas

  • Regioselectivity in Methylation: The methylation of the 4-hydroxy-2-thioxo-1,2-dihydroquinoline-3-carboxylate core is not straightforward. Initial S-methylation is highly regioselective. However, subsequent methylation of the resulting S-methylated product leads to a mixture of O- and N-methylated products, with O-methylation being predominant. This selectivity is influenced by the base used and reaction conditions.
  • Steric and Electronic Factors: Quantum chemical calculations revealed that while the nitrogen and oxygen atoms in the anion have similar negative charges, steric hindrance around the nitrogen atom favors methylation at the oxygen.
  • Structural Confirmation: Single-crystal X-ray diffraction provided definitive structural confirmation of the synthesized compounds, revealing details like intramolecular hydrogen bonding and crystal packing.
  • HBV Inhibition Potential: Molecular docking simulations predicted that the synthesized quinoline derivatives could act as potent inhibitors of HBV replication.
  • Experimental Validation: In vitro studies confirmed that compounds 3, 4, and 6 exhibit significant inhibition of HBV replication at a 10 µM concentration, with low cytotoxicity.

Key Results

  • Synthesis of S-methylated product (3): Methyl 4-hydroxy-2-(methylthio)quinoline-3-carboxylate (3) was obtained in high yield (81%) via S-methylation.
  • Synthesis of O- and N-methylated products (4 and 5): Subsequent methylation of compound 3 yielded methyl 4-methoxy-2-(methylthio)quinoline-3-carboxylate (4) as the major product (80-99%) and methyl 1-methyl-2-(methylthio)-4-oxo-1,4-dihydroquinoline-3-carboxylate (5) as a minor product (1-20%).
  • HBV Inhibition: Compounds 3, 4, and 6 demonstrated significant HBV inhibition (ranging from 68% to 83%) at 10 µM concentration, with cell survival rates above 78%.
  • Docking Scores: The synthesized compounds showed high binding affinity scores and binding energies comparable to or better than a reference compound, suggesting good potential as HBV inhibitors.

Limitations and Future Work

  • Regioselectivity Control: While the study established regioselectivity trends, achieving complete selectivity for either O- or N-methylation in the second step might require further optimization of reaction conditions or the development of more sophisticated synthetic strategies.
  • Combinatorial Library Design: The authors suggest that the established regioselectivity can serve as a basis for designing focused libraries of alkylated quinolines. Future work could involve synthesizing a broader range of derivatives based on these findings.
  • Mechanism of Action: While the compounds show promise as HBV inhibitors, the precise mechanism of action (e.g., targeting viral entry, replication, or assembly) beyond capsid inhibition needs further investigation.
  • In Vivo Studies: The current study focuses on in vitro results. Future research would necessitate in vivo studies to assess the efficacy and safety of these compounds in animal models.

Summary updated

Abstract

Consecutive alkylation of 4-hydroxy-2-thioxo-1,2-dihydroquinoline-3-carboxylate by CH<sub>3</sub>I has been investigated to establish regioselectivity of the reaction for reliable design and synthesis of combinatorial libraries. In the first stage, the product of S-methylation-methyl 4-hydroxy-2-(methylthio)quinoline-3-carboxylate was obtained. The subsequent alkylation with CH<sub>3</sub>I led to the formation of both <i>O</i>- and <i>N</i>-methylation products mixture-methyl 4-methoxy-2-(methylthio)quinoline-3-carboxylate and methyl 1-methyl-2-(methylthio)-4-oxo-1,4-dihydroquinoline-3-carboxylate with a predominance of <i>O</i>-methylated product. The structure of synthesized compounds was confirmed by means of elemental analysis, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, LC/MS, and single-crystal X-ray diffraction. The quantum chemical calculations of geometry and electron structure of methyl 4-hydroxy-2-(methylthio)quinoline-3-carboxylate's anion were carried out. According to molecular docking simulations, the studied compounds can be considered as potent inhibitors of Hepatitis B Virus replication. Experimental in vitro biological studies confirmed that studied compounds demonstrated high inhibition of HBV replication in 10 µM concentration.
BibTeX
@inproceedings{kovalenko2020methylation,
  author = {Sergiy М. Kovalenko and Oleksandr G. Drushlyak and Svitlana V. Shishkina and Irina S. Konovalova and Illia O. Mariutsa and N. D. Bunyatyan and Dmitry V. Kravchenko and Vladimir V. Ivanov and Alexandre V. Ivachtchenko and Thierry Langer},
  title = {{Methylation of Methyl 4-Hydroxy-2-thioxo-1,2-dihydroquinoline-3-carboxylate: Synthetic, Crystallographic, and Molecular Docking Studies}},
  booktitle = {Molecules},
  year = {2020},
  doi = {10.3390/molecules25184238},
}
Figure